More importantly, in view of the FLAURA study, osimertinib was recommended as the first-line treatment of advanced NSCLC patients possessing EGFR-activating mutations, regardless of T790M status [22–25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.